Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Santen’s Corporate Philosophy Framework
Santen’s Corporate Philosophy Framework
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Digital Transformation
Digital Transformation
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Development Process
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data
Social Data
Governance Data
GRI Standards Content Index
Sustainability Library
External Assessment
News
Home
News
2025 News
Press Release
IR News
Information
Press Release
12.23.2025
Santen Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults
12.22.2025
Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
12.05.2025
Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List
12.03.2025
Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases
10.23.2025
Santen Launches SETANEO® Ophthalmic Solution 0.002% in Japan for the Treatment of Glaucoma and Ocular Hypertension
Press Release
IR News
12.23.2025
Santen Launches Verkazia® (Ciclosporin Eye Drops (III) ) in China For the Treatment of Severe Vernal Keratoconjunctivitis (VKC) in Children and Young Adults
12.22.2025
Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%, a Treatment for Acquired Blepharoptosis
12.05.2025
Aflibercept intraocular injection kit 40 mg/mL Bayer Listed in NHI Drug Price List
12.03.2025
Santen and SERI Collaborate to Advance Disease-Modifying Therapies for Major Eye Diseases
11.20.2025
On December 1, Resumption of Shipments for Dry Eye Treatment “DIQUAS LX Ophthalmic Solution 3%”
IR News
Information
09.04.2025
Santen Helps Families Learn about Eye Health through “Learning Festival Summer 2025” Interactive Workshop
06.09.2025
Santen joins Mainichi Shimbun’s Vision Consortium
05.30.2025
Santen Signs the Joint Policy Statement on Protecting Children’s Vision in the Digital Age in Europe
Information
News Archive
